CorMedix (CRMD) Set to Announce Earnings on Wednesday

CorMedix (NASDAQ:CRMD) is anticipated to announce its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect CorMedix to post earnings of ($0.09) per share and revenue of $52.77 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 7:00 AM ET.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Thursday, August 13th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. CorMedix had a net margin of 40.49% and a return on equity of 40.52%. The firm had revenue of $101.93 million for the quarter, compared to analyst estimates of $96.04 million. On average, analysts expect CorMedix to post $0.54 EPS for the current fiscal year and $0.13 EPS for the next fiscal year.

CorMedix Price Performance

Shares of NASDAQ CRMD opened at $5.56 on Wednesday. CorMedix has a 1 year low of $5.30 and a 1 year high of $13.02. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.56 and a quick ratio of 2.36. The company’s 50-day moving average is $7.69 and its 200 day moving average is $7.65. The stock has a market capitalization of $433.35 million, a P/E ratio of 2.60, a P/E/G ratio of 1.01 and a beta of 1.48.

Wall Street Analyst Weigh In

CRMD has been the subject of several research analyst reports. Royal Bank Of Canada raised their price objective on shares of CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a report on Friday, August 14th. Weiss Ratings raised CorMedix from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Needham & Company LLC reduced their target price on CorMedix from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday. Finally, Oppenheimer began coverage on CorMedix in a report on Wednesday, September 23rd. They set an “outperform” rating and a $15.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $14.62.

CorMedix Company Profile

CorMedix Inc is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat life-threatening infections and inflammatory conditions. The company’s lead product is DefenCath, a catheter-lock solution containing taurolidine and citrate.

DefenCath is approved by the U.S. Food and Drug Administration for use in adult patients with kidney failure who are receiving chronic hemodialysis through a central venous catheter. It is intended to reduce the risk of catheter-related bloodstream infections, a significant complication for patients who depend on long-term vascular access.